CD20 항체 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 예측 기간의 성장은 첨단암 면역 치료에 대한 수요 증가, 자가면역질환 유병률 증가, 바이오시밀러 CD20 항체 채용 확대, 병용요법 적용 확대, 바이오의약 연구에 대한 투자 증가, 맞춤형 의료에 대한 의식의 고조 등이 있습니다. 주요 동향으로서는 차세대 CD20 항체의 개발, 항체 약물 복합체의 발전, 항체 설계에 있어서의 인공지능의 통합, 이중 특이성 항체 기술의 향상, CD20을 표적으로 하는 CAR-T 세포 치료의 대두, 딜리버리 강화를 위한 나노 테크놀로지의 채용 등이 있습니다.
B세포성 악성종양의 유병률 증가는 향후 몇 년간의 CD20 항체 시장의 확대를 견인할 것으로 예측됩니다. 환경폭로, 라이프스타일의 변화, 검출방법의 진보, 면역계의 변화 등 다양한 요인이 관여하고 있습니다. 예를 들어 미국을 거점으로 하는 비영리의 의학 단체인 미국 심장병학회의 2024년 보고서에 따르면 2025년에는 성인·소아를 포함해 약 8만 350명(남성 4만 5,140명, 여성 3만 5,210명)이 비호지킨 림프종(NHL)으로 진단될 것으로 추정되고 있습니다. 또한, 약 1만 9,390명(남성 1만 1,060명, 여성 8,330명)이 이 암으로 사망할 것으로 예측되고 있습니다.
CD20 항체 시장의 선도 기업들은 치료 접근성을 개선하고 의료 비용을 낮추며 B세포 악성 종양 및 자가 면역 질환에 대한 저렴하고 효과적인 치료제에 대한 증가하는 수요를 충족하기 위해 바이오시밀러와 같은 기술 발전에 우선순위를 두고 있습니다. 바이오시밀러란 안전성, 순도, 유효성에 큰 차이가 없으며, 이미 승인된 기준 제제와 닮은 생물학적 제제를 말합니다. 예를 들어, 2024년 7월, 인도에 본사를 둔 제약 회사인 닥터 레디스 래버러토리즈는 미국 식품의약국(USFDA)으로부터 리툭시맙 바이오시밀러 후보에 대한 완전 답변서(CRL)를 받았다고 발표했습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 CD20 항체 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 CD20 항체 시장 : 성장률 분석
- 세계의 CD20 항체 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 CD20 항체 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 CD20 항체 전체 시장(TAM)
제6장 시장 세분화
- 세계의 CD20 항체 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 단클론 항체
- 다클론 항체
- 세계의 CD20 항체 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 유세포 분석
- 효소결합면역흡착분석(ELISA)
- 웨스턴 블롯
- 면역침전
- 면역형광법
- 세계의 CD20 항체 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 전문 클리닉
- 외래수술센터(ASC)
- 기타 최종 사용자
- 세계의 CD20 항체 시장 : 단클론 항체 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 리툭시맙
- 오비누투주맙
- 오파투무맙
- 세계의 CD20 항체 시장 : 다클론 항체 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 기존 다클론 항체
- 인간 다클론 항체
- 재조합 다클론 항체
제7장 지역별/국가별 분석
- 세계의 CD20 항체 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 CD20 항체 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- CD20 항체 시장 : 경쟁 구도
- CD20 항체 시장 : 기업 프로파일
- F Hoffmann-La Roche AG 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck & Co Inc 개요, 제품 및 서비스, 전략 및 재무 분석
- Thermo Fisher Scientific Inc 개요, 제품 및 서비스, 전략 및 재무 분석
- Novartis AG 개요, 제품 및 서비스, 전략 및 재무 분석
- GlaxoSmithKline plc 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Amgen Inc
- Teva Pharmaceutical Industries Ltd
- Biogen Inc
- Genentech Inc
- Bio-Rad Laboratories Inc
- Genmab A/S
- Bio-Techne
- LFB Biotechnologies SA
- Abcam Limited
- Sino Biological Inc
- Mylan NV
- Immunomedics Inc
- Spectrum Pharmaceuticals Inc
- MyBiosource Inc
- IGM Biosciences Inc
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- CD20 항체 시장(2029년) : 새로운 기회를 제공하는 국가
- CD20 항체 시장(2029년) : 새로운 기회를 제공하는 부문
- CD20 항체 시장(2029년) : 성장 전략
제36장 부록
KTH
CD20 antibodies are monoclonal antibodies that specifically target CD20, a protein present on the surface of B cells, a type of white blood cell involved in the immune response. These antibodies are primarily used to treat conditions associated with abnormal B-cell function, including cancers and autoimmune diseases. Their primary role is to bind to the CD20 protein on B cells and initiate their destruction.
The primary end users of CD20 antibodies include hospitals, specialty clinics, ambulatory surgical centers, and others. These antibodies are utilized in various applications such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), western blot, immunoprecipitation, and immunofluorescence. CD20 antibodies are categorized into two main types, monoclonal and polyclonal antibodies. Monoclonal antibodies are laboratory-engineered proteins designed to bind to specific targets, such as the CD19 antigen found on B cells.
The CD-20 antibody market research report is one of a series of new reports from The Business Research Company that provides CD-20 antibody market statistics, including CD-20 antibody industry global market size, regional shares, competitors with a CD-20 antibody market share, detailed CD-20 antibody market segments, market trends and opportunities, and any further data you may need to thrive in the CD-20 antibody industry. This CD-20 antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The CD20 antibody market size has grown rapidly in recent years. It will grow from $9.94 billion in 2024 to $10.99 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to the increasing prevalence of B-cell malignancies, the rising incidence of autoimmune diseases, the growing demand for targeted therapies, the increasing approvals of biosimilars, rising healthcare expenditure, improvements in healthcare infrastructure, and greater awareness of the benefits of immunotherapy.
The CD20 antibody market size is expected to see rapid growth in the next few years. It will grow to $16.24 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to the rising demand for advanced cancer immunotherapies, the increasing prevalence of autoimmune disorders, the growing adoption of biosimilar CD20 antibodies, the expanding applications in combination therapies, the increasing investment in biopharmaceutical research, and the growing awareness of personalized medicine. Key trends include the development of next-generation CD20 antibodies, advancements in antibody-drug conjugates, the integration of artificial intelligence in antibody design, improvements in bispecific antibody technology, the rise of CAR-T cell therapies targeting CD20, the adoption of nanotechnology for enhanced delivery, and advancements in high-throughput screening methods.
The growing prevalence of B-cell malignancies is anticipated to drive the expansion of the CD20 antibody market in the coming years. B-cell malignancies refer to the increasing incidence of cancers affecting B cells, a type of white blood cell crucial to the immune response. Various factors contribute to this rise, including an aging population, genetic predispositions, environmental exposures, lifestyle changes, advancements in detection methods, and alterations in the immune system. CD20 antibodies, such as rituximab, play a critical role in targeting and eliminating malignant B-cells in conditions such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, thereby improving treatment outcomes. For instance, a 2024 report by the American College of Cardiology, a US-based nonprofit medical association, estimates that in 2025, approximately 80,350 individuals (45,140 males and 35,210 females), including both adults and children, will be diagnosed with non-Hodgkin lymphoma (NHL). Furthermore, around 19,390 people (11,060 males and 8,330 females) are projected to succumb to this cancer. As a result, the increasing occurrence of B-cell malignancies is propelling the expansion of the CD20 antibody market.
Leading companies in the CD20 antibody market are prioritizing technological advancements such as biosimilars to improve treatment accessibility, lower healthcare costs, and meet the growing need for affordable and effective therapies for B-cell malignancies and autoimmune diseases. Biosimilars are biologic medical products that closely resemble an already approved reference product without any significant differences in safety, purity, or efficacy. For example, in July 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, announced that it had received a complete response letter (CRL) from the US Food and Drug Administration (USFDA) for its rituximab biosimilar candidate. The company intends to collaborate with the USFDA to resolve all concerns within the designated timeframe, aiming to introduce the biosimilar rituximab to patients in the United States. Rituximab biosimilar functions by targeting the CD20 protein on the surface of B-cells, triggering a response that leads to the destruction of these abnormal or overactive B-cells.
In October 2024, GSK plc, a UK-based biopharmaceutical and biotechnology company, acquired CMG1A46, a dual CD19 and CD20-targeted T cell-engager (TCE) currently in clinical development, from Chimagen Biosciences for an undisclosed sum. Through this acquisition, GSK aims to develop and commercialize CMG1A46, focusing on B cell-driven autoimmune diseases such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with the potential for expansion into related autoimmune conditions. Chimagen Biosciences, a China-based clinical-stage biotechnology firm, specializes in discovering and developing novel multi-specific T cell-engagers and NK cell-engagers.
Major players in the CD20 antibody market are F Hoffmann-La Roche AG, Merck & Co Inc, Thermo Fisher Scientific Inc, Novartis AG, GlaxoSmithKline plc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Biogen Inc, Genentech Inc, Bio-Rad Laboratories Inc, Genmab A/S, Bio-Techne, LFB Biotechnologies SA, Abcam Limited, Sino Biological Inc, Mylan NV, Immunomedics Inc, Spectrum Pharmaceuticals Inc, MyBiosource Inc, IGM Biosciences Inc, and TG Therapeutics Inc.
North America was the largest region in the CD20 antibody market in 2024. The regions covered in CD20 antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the CD20 antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The CD20 antibody market consists of sales of rituximab, obinutuzumab, and ofatumumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
CD20 Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cd20 antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cd20 antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cd20 antibody market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Monoclonal Antibody; Polyclonal Antibody
- 2) By Application: Flow Cytometry; Enzyme-Linked Immunosorbent Assay (ELISA); Western Blot; Immunoprecipitation; Immunofluorescence
- 3) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End Users
- Subsegments:
- 1) By Monoclonal Antibody: Rituximab; Obinutuzumab; Ofatumumab
- 2) By Polyclonal Antibody: Conventional Polyclonal Antibodies; Human Polyclonal Antibodies; Recombinant Polyclonal Antibodies
- Companies Mentioned: F Hoffmann-La Roche AG; Merck & Co Inc; Thermo Fisher Scientific Inc; Novartis AG; GlaxoSmithKline plc
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. CD20 Antibody Market Characteristics
3. CD20 Antibody Market Trends And Strategies
4. CD20 Antibody Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global CD20 Antibody Growth Analysis And Strategic Analysis Framework
- 5.1. Global CD20 Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global CD20 Antibody Market Growth Rate Analysis
- 5.4. Global CD20 Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global CD20 Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global CD20 Antibody Total Addressable Market (TAM)
6. CD20 Antibody Market Segmentation
- 6.1. Global CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monoclonal Antibody
- Polyclonal Antibody
- 6.2. Global CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Flow Cytometry
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot
- Immunoprecipitation
- Immunofluorescence
- 6.3. Global CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Other End Users
- 6.4. Global CD20 Antibody Market, Sub-Segmentation Of Monoclonal Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Rituximab
- Obinutuzumab
- Ofatumumab
- 6.5. Global CD20 Antibody Market, Sub-Segmentation Of Polyclonal Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Conventional Polyclonal Antibodies
- Human Polyclonal Antibodies
- Recombinant Polyclonal Antibodies
7. CD20 Antibody Market Regional And Country Analysis
- 7.1. Global CD20 Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global CD20 Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific CD20 Antibody Market
- 8.1. Asia-Pacific CD20 Antibody Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China CD20 Antibody Market
- 9.1. China CD20 Antibody Market Overview
- 9.2. China CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India CD20 Antibody Market
- 10.1. India CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan CD20 Antibody Market
- 11.1. Japan CD20 Antibody Market Overview
- 11.2. Japan CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia CD20 Antibody Market
- 12.1. Australia CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia CD20 Antibody Market
- 13.1. Indonesia CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea CD20 Antibody Market
- 14.1. South Korea CD20 Antibody Market Overview
- 14.2. South Korea CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe CD20 Antibody Market
- 15.1. Western Europe CD20 Antibody Market Overview
- 15.2. Western Europe CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK CD20 Antibody Market
- 16.1. UK CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany CD20 Antibody Market
- 17.1. Germany CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France CD20 Antibody Market
- 18.1. France CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy CD20 Antibody Market
- 19.1. Italy CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain CD20 Antibody Market
- 20.1. Spain CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe CD20 Antibody Market
- 21.1. Eastern Europe CD20 Antibody Market Overview
- 21.2. Eastern Europe CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia CD20 Antibody Market
- 22.1. Russia CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America CD20 Antibody Market
- 23.1. North America CD20 Antibody Market Overview
- 23.2. North America CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA CD20 Antibody Market
- 24.1. USA CD20 Antibody Market Overview
- 24.2. USA CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada CD20 Antibody Market
- 25.1. Canada CD20 Antibody Market Overview
- 25.2. Canada CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America CD20 Antibody Market
- 26.1. South America CD20 Antibody Market Overview
- 26.2. South America CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil CD20 Antibody Market
- 27.1. Brazil CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East CD20 Antibody Market
- 28.1. Middle East CD20 Antibody Market Overview
- 28.2. Middle East CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa CD20 Antibody Market
- 29.1. Africa CD20 Antibody Market Overview
- 29.2. Africa CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. CD20 Antibody Market Competitive Landscape And Company Profiles
- 30.1. CD20 Antibody Market Competitive Landscape
- 30.2. CD20 Antibody Market Company Profiles
- 30.2.1. F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
31. CD20 Antibody Market Other Major And Innovative Companies
- 31.1. Amgen Inc
- 31.2. Teva Pharmaceutical Industries Ltd
- 31.3. Biogen Inc
- 31.4. Genentech Inc
- 31.5. Bio-Rad Laboratories Inc
- 31.6. Genmab A/S
- 31.7. Bio-Techne
- 31.8. LFB Biotechnologies SA
- 31.9. Abcam Limited
- 31.10. Sino Biological Inc
- 31.11. Mylan NV
- 31.12. Immunomedics Inc
- 31.13. Spectrum Pharmaceuticals Inc
- 31.14. MyBiosource Inc
- 31.15. IGM Biosciences Inc
32. Global CD20 Antibody Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The CD20 Antibody Market
34. Recent Developments In The CD20 Antibody Market
35. CD20 Antibody Market High Potential Countries, Segments and Strategies
- 35.1 CD20 Antibody Market In 2029 - Countries Offering Most New Opportunities
- 35.2 CD20 Antibody Market In 2029 - Segments Offering Most New Opportunities
- 35.3 CD20 Antibody Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
